Zymeworks Profit Margin 2016-2022 | ZYME

Current and historical gross margin, operating margin and net profit margin for Zymeworks (ZYME) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Zymeworks net profit margin as of June 30, 2022 is 30.15%.
Zymeworks Annual Profit Margins
Zymeworks Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.553B $0.412B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.403B 8.85
GSK (GSK) United Kingdom $75.578B 9.48
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.457B 19.38
Ginkgo Bioworks Holdings (DNA) United States $2.632B 0.00
Arcus Biosciences (RCUS) United States $1.318B 0.00
Biohaven (BHVN) United States $0.957B 0.00
Emergent Biosolutions (EBS) United States $0.469B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.166B 0.00
Enzo Biochem (ENZ) United States $0.125B 0.00
SQZ Biotechnologies (SQZ) United States $0.017B 0.00
Gelesis Holdings (GLS) United States $0.014B 0.00